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Infection with HIV-1 greatly increases the risk of active tuberculosis (TB). Although hypotheses suggest
HIV-1 disrupts Mycobacterium tuberculosis (Mtb) granuloma function, few studies have examined this
directly. The objective of this study was to determine what evidence exists about the effect HIV-1 co-
infection has upon Mtb granulomas. A systematic search of PubMed, Web of Science, and Medline up to
20 March 2015 was conducted, to identify studies comparing Mtb-infected tissue from HIV-1 infected
and uninfected persons, or HIV-1 infected persons with stratiﬁed peripheral CD4 T cell (pCD4) counts.
We summarized ﬁndings that focused on how HIV-1 changes granuloma formation, bacterial presence,
cellular composition, and cytokine production. Nineteen studies with a combined sample size of 899
persons were included. Although studies frequently were limited by variable or inadequately described
deﬁnitions of outcomes and analytical methods, HIV-1 was found to be associated with increased
bacillary load within Mtb-infected tissue. Reductions in pCD4 counts within co-infected persons asso-
ciated with both poorer granuloma formation and higher bacterial load. The high degree of heterogeneity
among studies combined with experimental limitations made it difﬁcult to conclusively support previ-
ously published and prevalent hypotheses about HIV-1/Mtb co-infection granulomas. To elucidate the
validity of these hypotheses we have described areas that can be improved in future studies in order to
clarify the inﬂuence HIV-1 co-infection has upon the Mtb granuloma.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) and HIV-1 are two of the leading infectious
causes of death worldwide and TB is the leading cause of death
among HIV-1 infected persons [1]. Once infected with Mycobacte-
rium tuberculosis (Mtb), HIV-1 infected persons have increased
morbidity and mortality due to TB compared to HIV-1 uninfected
persons [2]. As peripheral CD4 T cell (pCD4) counts fall, suscepti-
bility to active and disseminated TB increase, however, HIV-1
infected persons with relatively preserved pCD4 counts are also
at increased risk [3]. It has been hypothesized that the primaryBiomedical Science Tower 3,
h, PA 15261, USA.
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Ltd. This is an open access article ucause for increased TB susceptibility in HIV-1 infected persons is
due to immunological disruptions of the Mtb granuloma [4,5].
The granuloma is the hallmark of TB. Granulomas consist of a
collection of organized immunological cells that form in response
to Mtb infection [6]. Granulomas commonly consist of infected and
recruited macrophages, differentiated epithelioid cells, all sur-
rounded by a lymphocyte layer. The relationship between the
granuloma and TB is complex and not fully understood because
granulomas can prevent dissemination and kill Mtb, but also allow
persistence of Mtb and even be permissive to its growth [7,8]. This
illustrates the delicate balance between bacterial growth and death
within the microenvironment of the granuloma and that granu-
lomas form an incompletely effective or even bacterium-
permissive immunological response [7,9]. It is hypothesized that
HIV-1 disrupts this balance by causing granulomas to be more
disorganized, killing resident CD4 T cells, and dysregulating normal
T cell, and macrophage function (Table 1) [4,5,10e14], leading to annder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Hypotheses how HIV-1 manipulates Mtb granulomas.
Review (ﬁrst author, year published) Main hypotheses regarding granulomas in HIV-1/Mtb co-infected persons
Ledru, 1999 [10] HIV-1's ability to manipulate cytokine and nitric oxide production that are recruited to the granuloma may play an
important role in increasing bacterial dissemination.
Bocchino, 2000 [11] Poor granuloma formation within co-infected persons most likely results from a disruption in the pro- and anti-
inﬂammatory production of cytokines and an increase in cell death of CD4 T cells.
Lawn, 2002 [5] Granulomas within co-infected persons will be poorly formed and contain increased bacterial growth through the
impairment of cellular recruitment and cell-mediated granulomatous response.
Diedrich, 2011 [4] Granulomas within co-infected persons will have impaired architecture, reduced CD4 T cell counts, impaired T cell and
macrophage function, and increased cell death.
Kwan, 2011 [12] HIV-1 replication may be induced by Mtb-infected macrophages that will indeed lead to HIV-1 infection of adjacent
macrophages and CD4 T cells and activated CD4 T cells will increase HIV-1 replication
Geldmacher, 2012 [13] Preferential depletion of Mtb-speciﬁc and total CD4 T cells may play a signiﬁcant role in granuloma disruption within
HIV-1 infected persons
Ansari, 2013 [14] HIV-1 enters granulomas and causes CD4 T cell apoptosis, depletion, and disrupted recruitment of T cells, which leads to
granuloma disorganization.
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disease.
Many studies in humans that support these hypotheses have
measured immunological responses within non-tissue resident
cells: peripheral blood mononuclear cells (PBMC), bronchoalveolar
ﬂuid (BALF), and pericardial ﬂuid (PCF) [15e18]. These studies have
demonstrated impaired Mtb-speciﬁc T cell activity [15,16,18] and
killing of Mtb-speciﬁc peripheral CD4 Tcells [19], and total BAL CD4
T cells [17] in persons infected with HIV-1. Although these data are
convincing, there are signiﬁcant variations in cellular composition
andMtb-speciﬁc immunological responses within PBMC, BALF, PCF,
and granulomas [20,21]. Extrapolating data from non-tissue resi-
dent cells to what is occurring within granulomas may not be
appropriate [22]. This illuminates a need to study human granu-
lomas directly in HIV-1/Mtb co-infected persons to better under-
stand how HIV-1 manipulates the TB granuloma. Understanding
how HIV-1 manipulates granulomas directly will elucidate the
mechanistic cause HIV-1 exploits that increases TB susceptibility.
We systematically reviewed HIV-1/Mtb co-infection literature
that examined Mtb granulomas directly. The objective of this sys-
tematic review and meta-analysis was to elucidate how Mtb-
infected tissues differ between HIV-1 infected and uninfected
persons. We focused on studies that reported how HIV-1 changed:
granuloma formation [23e29], granuloma organization
[23,26e28,30e35], granuloma caseation [23,25,26,29e33], Mtb
growth [23e25,27,31,32,35,36], cellular populations [23,26,30e33],
cytokine expression [30,31,37] and HIV-1 virion presence within
excised tissue [33,38]. To help reduce some of the variability
observed within this literature our second objective of this review
was to illuminate future strategies to study, analyze, and report
granuloma-based data.2. Methods
2.1. Search strategy and selection criteria
PubMed, Web of Science, and Medline were searched using
predetermined combinations of terms (Supplemental Table 1) for
relevant peer reviewed studies (through 20 March 2015) that re-
ported histological data in TB diseased tissue from HIV-1/Mtb co-
infected persons. We reviewed original articles published in all
languages. In addition to the database search, we screened citations
in the full-text articles reviewed here, published reviews, book
chapters, and suggested papers from experts in the ﬁeld.
The primary objective of this review was to identify how Mtb
granulomas from HIV-1/Mtb co-infected persons differed from
granulomas obtained from HIV-1 uninfected persons. Studies wereeligible for inclusion if they compared the histology of Mtb infected
tissue from HIV-1 infected and uninfected persons, or from HIV-1
infected persons with stratiﬁed pCD4 counts. Studies were
required to include an acceptable means of deﬁning HIV-1-infected
and uninfected groups (either HIV-1 serology or a documented past
history of HIV-1 infection, or for studies prior to 1990, an acceptable
HIV/AIDS diagnosis by World Health Organization criteria at the
time of publication) and conﬁrming TB diagnosis (microbiology or
histology consistent with TB, with or without a consistent clinical
picture including course of illness and response to treatment).
Studies were excluded if themethod of biopsy was only ﬁne-needle
aspiration (FNA) as this method of excisionwas unlikely to preserve
granuloma architecture and may not capture entire granulomas
within the target tissue. Where studies reported or appeared to
report on the same or overlapping persons, the results from the
earlier study were excluded. Reviewers independently assessed the
eligible articles for inclusion and exclusion criteria; disagreements
were resolved by consensus. The included studies were assessed for
quality of study design and potential limitations to ﬁndings.
2.2. Data extraction
Results from the individual studies were categorized into the
following outcomes for comparison between HIV-1/Mtb co-infec-
ted and HIV-1 uninfected persons, or HIV-1-infected with stratiﬁed
pCD4 counts: 1) proportion of biopsied samples with granulomas
present, 2) quality of granuloma formation (quality of granuloma
formation was deﬁned independently within each study), 3)
cellular and cytokine presence, 4) proportion of biopsied samples
containing Mtb (acid fast bacilli [AFB] or culture positivity [CFU], 5)
bacillary load within AFBþ samples, and 6) HIV-1 virion presence.
2.3. Statistical analysis
For outcomes where studies reported individual quantitative or
semi-quantitative results for the different outcomes HIV-1/Mtb co-
infected and Mtb-only infected persons, a meta-analysis was per-
formed using the Cochrane Database's RevMan program. We
calculated summative risk ratios for changes in 1) granuloma
presence, 2) quality of granuloma formation, 3) AFB presence 4)
CFU in HIV-1/Mtb-co-infected versus Mtb-only infected persons
and 5) AFB load. Where results were categorically scored and not
simply dichotomous (for quality of granuloma formation and AFB
load), the proportions of persons in each group with the highest
scores (for well-formed granulomas and AFB load) or lowest scores
(for poorly formed granulomas) were used in meta-analyses. Data
sets were treated as dichotomous and risk ratio with 95% CIs were
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analysis model. Heterogeneity was assessed with I2 statistics and
deﬁned as low (I2 25%), moderate (25% < I2 75%), high (I2>75%).
3. Results
Our initial search yielded 3645 abstracts and titles (Figure 1).
After review of these abstracts, titles, and where appropriate, full
studies, 60 studies were identiﬁed that examined the histopathol-
ogy of Mtb infection in persons co-infected with HIV-1. Eight
studies were excluded because, while they described the ﬁndings
in tissue from HIV-1/Mtb co-infected persons, no comparison was
made to either HIV-1 uninfected persons, or between different HIV-
1 persons at different stages of HIV-1 infection or pCD4 count
[39e46]. Sixteen studies were excluded, because their results were
based on FNA [47e62]. Four studies did not adequately deﬁne HIV-
1 [63e66] and one did not adequately deﬁne HIV-1 or TB status
[67]. Four studies did not differentiate results between Mtb and
other mycobacteria [68e71]. One study may have been biased byFigure 1. Studypersons having co-morbidities [72]. Two studies [31,33] reanalyzed,
at least in part, some results from persons in previous studies
[73,74]. For these overlapping studies, results from the later pub-
lished study were included [31,33]. Five studies did not sufﬁciently
examine tissue samples [75e79].
Nineteen unique studies [23e38,80e82] were included in
this review (Table 2). A total of 413 Mtb-only infected persons
(with a range between 3 and 108 persons, median n ¼ 14) and
486 HIV-1/Mtb co-infected persons (range: 5e109, n ¼ 13). The
site of TB disease within each study was varied: ﬁve examined
lymph node [26,31,32,80,83], seven examined pleura
[23,27,29,35e37,82], three examined lung [24,28,30], one each
examined spine [33], pericardium [25], brain [81], and one
study analyzed multiple tissues from different persons (lymph
node, lung, pleura, bone marrow) [34]. pCD4 counts were
stratiﬁed for comparison in HIV-1/Mtb co-infected persons in
ﬁve studies [23,28,31,34,38]. One study described stratiﬁed
pCD4 counts without presenting individual data [35]. Two of
the pCD4-stratiﬁed studies examined only HIV-1/Mtb co-selection.
Table 2
Study summaries.
Study (ﬁrst author,
date, country)
Number of persons
with Mtb-only
(mean age)
Number of HIV-1
co-infected persons
(mean age)
HIV-1 stage and
mean pCD4
Biopsy site Key measurements
relevant to review
Main ﬁndings (co-
infected vs Mtb-
only)
Comments
Bezuidenhout
2009
South Africa
[37]
6
(38)
6
(34$5)
Early stage-
qualiﬁed by no OI
Pleura - Granuloma
necrosis and counts
- IFNg, TNF, IL12,
IL4 mRNA
↑- Granuloma
necrosis
↑- TNF mRNA
production
?- IFNg, TNF, IL12,
IL4 mRNA
production
- 166 granulomas
from 12 patients
but analyzed
granulomas as
independent
entities, which may
have biased results
toward persons
that contained
more granulomas
- Methodology for
examining cytokine
production was
difﬁcult to interpret
and compare
among other
studies
- Selection of region
of interest (ROI)
was not described
- Granuloma
deﬁnitions were
not described
- No mention of
pathologists being
blinded
Conde
2003
Brazil
[82]
71
(37$2)*
13 Not stated Pleura AFB and CFU ↑ AFB smear
presence
 No signiﬁcant
difference in CFU
- The primary aim
of this study was to
investigate
diagnostic yield of
sputum induction
in pleural TB.
Pleural biopsy
tissue, however,
was examined as
part of the study
and the results
from this
incorporated to our
study.
- No blinding was
described
- *Mean age of all
persons within
study
Danaviah
2013
South Africa
[33]
9
(44$4)
13
(26$4)
544$6 þ- 315 Spine - Viral load (tissue
homogenate and
plasma)
- CD3, CD4, CD8
markers
- giant cell (GC)
counts
 Same granuloma
organization
 Same CD3%
↓ CD4%
↑ CD8%
- Further analysis of
persons from
previously
published study
[82]
- Selection of intact
granulomas may
have biased results
toward well-
formed granulomas
- Single CD4 and
CD8 markers used
may lead to non T
cells being
quantiﬁed
- Selection of ROI
not described.
- Granuloma
deﬁnitions were
not described
- No mention of
pathologists being
blinded
De Noronha
2007
4 5 Not stated Lung - Granuloma
organization,
architecture and
↑ Granuloma
disorganization
 Similar necrosis
- Autopsies
performed on
persons that died of
(continued on next page)
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Table 2 (continued )
Study (ﬁrst author,
date, country)
Number of persons
with Mtb-only
(mean age)
Number of HIV-1
co-infected persons
(mean age)
HIV-1 stage and
mean pCD4
Biopsy site Key measurements
relevant to review
Main ﬁndings (co-
infected vs Mtb-
only)
Comments
Brazil
[30]
composition (from
H&E), necrosis,
bacilli load, TNF,
TGF-b
↓ TNF production
 Similar TGFb
↑ AFB presence
stated (not
presented
individually)
pulmonary TB may
have biased results
towards more
severe TB disease.
- 3 blinded
pathologist were
used
- Selection of ROI
was not described
- Granuloma
deﬁnitions were
not described
Di Perri
1996
Italy
[28]
16
(32$5)
16
(30$7)
>400:3
200e400: 3
100e200: 3
<100: 7
Lung Granuloma
organization, AFB
load correlated
with stratiﬁed
pCD4 counts
↓ Granuloma
counts
↑ Poorly formed
granulomas
↓ Well formed
granulomas
↑ AFB presence and
load
 pCD4 counts
indirectly correlate
to ↑ bacterial load, ↑
poorly formed
granulomas, ↓ well
formed granulomas
- All patients were
sputum negative
prior to
bronchoscopy,
which may have
lead to selection
bias.
- Method of biopsy
e from area of
consolidation; or
right middle lobe or
lingual in case of no
focal or only
diffused
consolidation may
have biased results
- Multiple
pathologist
reviewers, however
no blinding
detailed.
- Granuloma and
AFB load
descriptions were
available
- Selection of ROI
was not described
Elliott
1993
Zambia
[36]
5 9 Not stated Pleura CFU  No signiﬁcant
difference in CFU
- Study described
clinical and
diagnostic
differences
between HIV-1
infected and
uninfected persons
with TB.
- No blinding was
described
Heyderman
1998
Zimbabwe
[23]
11-
(33)
63
(23)
191 (0e2009)
>500 11
200e490: 19
100e190: 6
<100: 14
Pleura Granuloma counts,
poorly formed,
caseation, GC, AFB
and CFU positive,
AFB load, stratiﬁed
pCD4
 No difference in
granuloma counts,
caseation,
formation, giant
cells, AFBþ or
CFUþ samples, or
scanty AFB
↑ Tissue with
numerous AFBþ
 pCD4 counts may
correlate to
increased bacterial
load
- 63 persons in co-
infected group,
- pCD4 stratiﬁed to
results.
- Granuloma
formation, scanty
and numerous AFB
loads were not
described.
- Selection of ROI
was not described.
- Blinded
pathologists were
not described.
Hochedez
2003
France
[80]
19
(38$5)
13
(36$5)
Not stated LN AFB, CFU,
Granuloma
presence, Caseation
 No signiﬁcant
difference in
granuloma
presence, AFB, CFU,
or caseation
- Method of
selection of ROI not
described
- Precise granuloma
descriptions were
not provided
Jones
1993
USA
[34]
NA 23 Stratiﬁed pCD4/
mm3 from 21
persons:
<101: 9
9 LN, 6 lung,
4 pleura,
4 bone marrow
Granulomatous
changes stratiﬁed
to pCD4 counts
 Granulomatous
changes observed
regardless of pCD4
counts.
- Granuloma
formation and
tissue AFB presence
were not primary
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Table 2 (continued )
Study (ﬁrst author,
date, country)
Number of persons
with Mtb-only
(mean age)
Number of HIV-1
co-infected persons
(mean age)
HIV-1 stage and
mean pCD4
Biopsy site Key measurements
relevant to review
Main ﬁndings (co-
infected vs Mtb-
only)
Comments
101e200: 5
201e299: 3
>300: 4
aim of this study
- Granulomatous
changes were not
deﬁned.
Kennedy
1992
USA
[24]
45 67 Not stated (likely
many late due to
year of study)
Lung Granuloma counts,
AFB and CFU
positivity
 No difference in
AFB smear or CFU
↓ Granuloma
presence
- The primary aim
of this study was to
assess the utility of
bronchoscopy in
sputum negative
persons in the
diagnosis of
pulmonary TB in
HIV-1 infected
patients, rather
than to assess
granuloma
differences
- 67 co-infected and
45 HIV-1
uninfected persons
were in this study.
- Granulomas were
not deﬁned
- Potential
sampling bias
associated with
bronchoscopic
biopsy site
selection technique
may have occurred
- Selection of ROI
was not described
- Blinded
pathologists were
not described
Luzze
2001
Uganda
[35]
33
(33)
109
(34)
Not stated Pleura Granuloma
formation, CFU,
BACTEC culture,
days to culture
positivity
↓ Well formed
granulomas
↑ CFU positivity
 No signiﬁcant
difference in
BACTEC culture
positivity or days to
positivity
 Granuloma
formation was not
different in persons
with fewer pCD4
counts
- The primary aim
of study was to
compare clinical,
radiographic and
diagnostic methods
in pleural TB
between HIV
infected and
uninfected persons
- Method of
granuloma
assessment is not
speciﬁcally
described.
- No blinding was
described
Muller
1994
Germany
[31]
8 8 Individual pCD4/
mm3:
100e200:4
200e300: 2
300-400: 2
Lymph node (LN) Necrosis, MNGC,
Epithelioid cell
layer, CD68,
lysozyme, a-1-anti-
chymotryp.,
Mac387, Ki-M8,
CD43, CD3, CD4,
CD8, CD25, HLA-
DR, Ki-67, CD22, IL-
1a, IL-1b, IL-6, TNF,
IFN-a, IFN-b.
Stratiﬁed to pCD4
counts
↓ well formed
epithelioid layer
within granulomas
↑* Neutrophil
↓GC, marginal
ﬁbrosis and
angiogenesis
 Same necrosis and
all other cellular
markers
↑* TNF, IFNa, IFNb,
IL6, IL1a, IL1b as
pCD4 counts reduce
- All results except
cytokine
production
appeared to overlap
with a previously
published paper
[83]
- Examined 22
histological
outcomes and
stratiﬁed pCD4
counts
- All measurements
were categorical
without detailed
descriptions
- Speciﬁc LN type is
not discussed
- No blinding or
selection of ROI
described
(continued on next page)
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Table 2 (continued )
Study (ﬁrst author,
date, country)
Number of persons
with Mtb-only
(mean age)
Number of HIV-1
co-infected persons
(mean age)
HIV-1 stage and
mean pCD4
Biopsy site Key measurements
relevant to review
Main ﬁndings (co-
infected vs Mtb-
only)
Comments
* Some conclusions
were difﬁcult to
determine because
of qualitative
nature of
measurements
Ngilimana
1996
Rwanda
[32]
3
(27)
12
(32)
Not stated LN Langhan cells,
Epithelioid cells,
lymphocytic cuff,
foamy
macrophages,
necrosis type, AFB
load, epithelioid
venule,
plasmocytes,
granuloma
formation
↓* Well formed
granulomas
↑ AFB load
↑* Epithelioid
macrophages
↓*Lymphocytes and
Lanhan cells
- Description of
granulomas was
detailed in
previously
published study
[51]
- Examined a 9
histological
outcomes in 12 co-
infected persons
and only 3Mtb only
persons-Speciﬁc LN
type was not
discussed,
- Blinding and ROI
selected were not
described
* All measurements
were categorical
Perfura-Yone
2011
Cameroon
[29]
108 with pleural
biopsy
81 with pleural
biopsy
Not stated Pleura Granuloma counts
and caseum.
 No difference in
granuloma
presence or
necrosis
↑ Necrosis within
persons with <200
pCD4/mm3
- Study focused on
clinical,
radiological,
hematological as
well as histological
picture in a high
number of persons
with tuberculous
pleural effusion.
- 108 Mtb-only and
81 co-infected
persons were
examined in this
study.
- The method for
selection of ROI not
described
- There was not
mention of blinding
of assessing
pathologists
Reuter
2006
South Africa
[25]
20 5 Not stated Pericardium Granuloma counts,
central necrosis,
CFU positivity
 No signiﬁcant
difference in
granuloma counts,
necrosis or AFB
presence
- Sub dividing 25
persons into 4
groups and 7
histopathological
outcomes resulted
in small 8 outcomes
containing only 1
person.
- Blinding and ROI
selected were not
described
- Granulomas were
not deﬁned
Shen
1988
USA
[26]
3 5 AIDS by CDC 1985
criteria (OI)
LN AFB, brief
granuloma
description,
epithelioid
macrophage
counts, CD3, CD4,
CD8, CD26, HLA-
DR, CD14
percentages
 No difference in
granuloma
formation
↑ AFB load stated
without data
↓ CD3 and CD4%
 No difference in
CD8%, but CD8 T
cells are distributed
throughout
granulomas
 No difference in
other markers
- Only 3 persons in
Mtb-only group
- Problematic
deﬁnition for 2
persons in HIV-1
group because they
were deﬁned as risk
factors and
symptoms
indicative of AIDS
related complex
without deﬁning
what satisﬁed this
e these patients
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Table 2 (continued )
Study (ﬁrst author,
date, country)
Number of persons
with Mtb-only
(mean age)
Number of HIV-1
co-infected persons
(mean age)
HIV-1 stage and
mean pCD4
Biopsy site Key measurements
relevant to review
Main ﬁndings (co-
infected vs Mtb-
only)
Comments
were deleted from
our analysis.
- 2 independent
observers were
used
- ROI and blinding
were not described
- Precise granuloma
descriptions were
not provided.
Trajman
1997
Brazil
[27]
27 9 Not speciﬁed Pleura Granuloma
presence,
formation, caseous
necrosis,
epithelioid cells, GC
 No difference in
granuloma counts
or formation
 No difference in
caseous necrosis,
epithelioid cells or
GC presence
- Outcomes
assessed by
impression of one
pathologist, but
with no clearly
described criteria
for outcomes.
- ROI and blinding
were not described
- Precise granuloma
descriptions were
not provided.
Tripathi
2014
India
[81]
5
(27$8)
5
(31$2)
Not stated Brain Granuloma
formation
↓ Well formed
granulomas in HIV-
1 co-infected
persons
- Granuloma
descriptions were
not a primary goal
of study
- Autopsies were
performed between
2 and 13$45 h post
mortem, which
may have biased
results
- Assessment of IL-
6, MIP-1a, IL-8, and
TNF-a described in
methods but not
reported in results.
Van Der Ende
1999 Germany
[38]
NA 9 Group 1:
>150 pCD4/mm3
Group 2 <50 pCD4/
mm3
LN HIV-1 RNA,
granuloma
presence and
formation from
stratiﬁed pCD4
counts
 Group 1-
inﬂammation was
disorganized with
no well-formed
granuloma
↑ HIV-1 RNA in and
near granulomas
than non-
granulomatous
areas (data not
presented in study).
 CD4 T cells
remained the main
source of HIV RNA
in both groups.
- Speciﬁc LN
excised not
identiﬁed
- Compared co-
infected patients at
different peripheral
CD4 counts.
- Only study to
directly examine
HIV-1 presence
within granuloma
at different pCD4
counts
- 2 persons with
<50 pCD4/mm3 and
M. avium complex
were excluded
from our analysis
- ROI was not
described
- Precise granuloma
descriptions were
not provided
C.R. Diedrich et al. / Tuberculosis 98 (2016) 62e76 69infected persons [34,38]. These studies typically included few
persons and techniques for deﬁning and assessing outcomes
such as granuloma presence and formation, AFB load and
cellular presence were variable and sometimes not deﬁned at
all. Histological analyses were also not always performed in a
blinded fashion and the methods for identifying regions of in-
terest (ROI) examined were not deﬁned. These limitations may
have biased results within each of the studies.3.1. Does HIV-1 co-infection reduce the granuloma presence in Mtb-
infected persons?
HIV-1 has been hypothesized to reduce Mtb granuloma forma-
tion [5]. If an infected person cannot form granulomas they may be
more susceptible to Mtb dissemination. To determine if this hy-
pothesis was true we examined the proportion of Mtb-infected
persons with granulomas visible in excised tissue was identiﬁed
Figure 2. ManteleHaenszel random effects risk ratio for Mtb granuloma presence in HIV-1 co-infected persons.
C.R. Diedrich et al. / Tuberculosis 98 (2016) 62e7670and compared between HIV-1-infected and -uninfected persons in
eight studies [23e29,80]. Granuloma presencewas calculated using
the proportion of excised tissue containing at least one granuloma.
One study was excluded from this analysis as granuloma presence
was a criteria for tissue selection [33] while another was excluded
because it reported total Mtb granulomas observed [37] and not
granulomas per excised tissue. The lowest granuloma score in one
study represented non-organized inﬂammatory patterns [28],
which were not counted as granulomas. For all these studies,
granuloma presence was a dichotomous variable, without quanti-
fying granulomas in each excised sample.
HIV-1 did not change the likelihood of excised tissue containing
granulomas. The proportion of persons with tissue that contained
granulomas varied widely for both groups across the studies. In
tissue from HIV-1 infected persons, Mtb granuloma presence
ranged from 19% [24] to 100% [26], and from HIV-1 uninfected
persons from 43% [24] to 100% [26]. All studies apart from two [26],
reported at least a slight reduction in granuloma presence within
HIV-1 infected persons. However, only one study reached statistical
signiﬁcance [24]. The probability ratio calculated based on forest
plot did not identify a signiﬁcant difference for granuloma presence
between the two groups (Figure 2, RR: 0.82, 0.65e1.03). Varying
pCD4 counts correlated to a difference in granuloma presence
within HIV-1/Mtb co-infected persons in one study [28] but not in
another [23].
3.2. Does HIV-1 co-infection change the quality of Mtb granuloma
formation?
The ability of granulomas to kill Mtb and prevent its dissemi-
nation, in part, relies on howwell they are organized [6]. It has been
hypothesized that HIV-1 disrupts normal granuloma formation
[4,5], which could increase TB susceptibility in HIV-1 infected
persons. To determine if HIV-1 changes Mtb granuloma formation
quality we identiﬁed eight studies that reported the presence of
well- or poorly-formed granulomas [23,26e28,30e32,35]. Tech-
niques used to score granuloma organization were highly variable
and included: an assessment of the presence of epithelioid cells,
lymphocytes and caseation [28,30], or focused on the organization
of the epithelioid cells alone [31]1. The remaining studies relied on
pathologist impressions only without providing a description
[23,26,27,32,35].
No quantiﬁable difference in the appearance of well- or poorly-
formed Mtb granulomas were observed in HIV-1 co-infected and
HIV-1 uninfected persons. Four studies presented ﬁndings for well-
and poorly-formed granulomas [27e29,32], while one presented
results for poorly-formed granulomas only [23] or well-formed
granulomas only [35] in HIV-1 co-infected and uninfected per-
sons. Four of the ﬁve studies that examined the presence of well-formed granulomas identiﬁed a non-statistically signiﬁcant
[28,31,32] or signiﬁcant [35] reduction in HIV-1 infected persons,
while the remaining study identiﬁed no difference [27]. Similarly,
three of ﬁve studies that quantiﬁed poorly-formed granulomas
identiﬁed a non-statistically signiﬁcant increase within co-infected
persons [28,31,32], while the remaining two identiﬁed no differ-
ence [23,27]. Forest plots for both well- and poorly-formed gran-
ulomas did not meet statistical signiﬁcance (Figure 3A: well-
formed: RR 0.33 [0.08, 1.26], 3B: poorly-formed: RR 2.63 [0.24,
28.91]).
Qualitative assessments of Mtb granuloma formation were
highly variable and inconclusive in both HIV-1 infected and HIV-
uninfected persons. Other studies described granuloma formation
quality between the two groups without presenting results from
individual persons [26,30,33,81]. Shen et al. [26], made an overall
statement that all ﬁve persons with AIDS and TB lymphadenitis
contained caseous granulomas similar to those in the HIV-1 unin-
fected persons. Danaviah et al. [33], also reported no difference in
granuloma formation between co-infected and singly infected
persons with spinal TB, but their method stated intact granulomas
were chosen for examination, a strategy that may have biased re-
sults toward well-formed granulomas. Conversely, De Noronha
et al. [30], reported three well-deﬁned zones (caseation, epithelioid
cell layer and lymphocytic cuff) within the granulomas of persons
with pulmonary TB without HIV-1 compared to atypical disorga-
nized arrangement of the granulomas located in co-infected per-
sons. Tripathi et al. [81], described the presence of well-formed
granulomas in the brain of HIV-1 uninfected persons with TB
meningitis but noted their absence in HIV-1 co-infected persons.
While it is widely believed the increased susceptibility of HIV-1
infected persons to disseminated TB is caused by impaired granu-
loma formation, we found the results reported in this area to be
conﬂicting and thus the evidence to support this hypothesis
lacking.
HIV-1 did not change the presence of caseous granulomas. A
hallmark of TB is the caseous granuloma [6], and to determine if
HIV-1 changes caseation necrosis we identiﬁed studies that quali-
tatively [30,31,33] or quantitatively [23,25,26,29,32,37] reported
caseous granuloma presence in co-infected and singly infected
persons. Most studies identiﬁed no difference in granulomatous
necrosis or caseation between co-infected and singly infected
persons [23,26,29,31]. Two studies reported less necrosis in co-
infected persons without statistical analysis [25,32]. Only one
study reported a statistically signiﬁcant increase in necrotic lung
granulomas in co-infected persons [37]. These data suggested that
HIV-1 co-infection did not change the likelihood of granulomas
becoming caseous.
pCD4 depletion associated with poorly formed Mtb granulomas
in HIV-1 co-infected persons. To determine if HIV-1 progression
Figure 3. ManteleHaenszel random effects risk ratio for well-formed- (A) and poorly-formed (B) granulomas in HIV-1 co-infected persons.
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studies that correlated pCD4 counts with granuloma formation in
co-infected persons [28,31,34,35,38]. Three studies reported more
poorly formed granulomas in those with lower pCD4 counts
[28,31,34]. One study described no correlation between pCD4
counts and granuloma appearance [35]. Di Perri et al. [28],
demonstrated that six persons with the lowest categorically
deﬁned granuloma scores (unorganized inﬂammation) had a mean
pCD4 of 49.2 pCD4/mm3 compared to the remaining ten persons
with a mean pCD4 of 238.6 pCD4/mm3. Similarly, Muller et al. [31],
reported well-formed granulomas in two persons with >300 pCD4/
mm3, a combination of well- and poorly-formed granulomas in
persons with 200e300 pCD4/mm3 and only necrosis and foamy
macrophages within lymph nodes of persons with <200 pCD4/
mm3. Van Der Ende et al. [38], reported an absence of well-formed
granulomas within the two HIV-1/Mtb co-infected persons with
<50 pCD4s/mm3, while the ﬁve persons with >170 pCD4/mm3
contained multiple well-formed granulomas. Granulomatous
changes were observed but not deﬁned, in 75% (9/12) of excised
tissues from HIV-1 co-infected persons with <101 pCD4/mm3,
although this reduction was not signiﬁcantly different from other
co-infected persons with higher pCD4 counts [34]. Taken together,
lower pCD4 counts in HIV-1 infected persons generally correlated
to poorer granuloma formation, particularly as pCD4 counts fall
below 50 pCD4/mm3.3.3. Does HIV-1 change the cellular composition of Mtb
granulomas?
It is hypothesized that T cells and macrophages, essential com-
ponents for normal granuloma activity, are preferentially killed or
manipulated by HIV-1 at the site of TB disease [4,5,13]. To deter-
mine if cellular composition of granulomas from HIV-1 co-infected
persons differ from HIV-1 uninfected persons we identiﬁed three
studies that compared the presence of T cells in two groups. The
studies that quantiﬁed T cell presence used single CD3, CD4, or CD8
antibodies for identiﬁcation [26,31,33], so the presence of
CD4þCD3- (macrophages, dendritic cells) and CD8þCD3- (NK cells)
non-T cells may have biased results by staining false positives.CD3, CD4, or CD8 T cell counts within granulomas were highly
variable. Two studies qualitatively identiﬁed fewer lymphocytes
within granulomas from co-infected persons [30,32], but did not
speciﬁcally identify the types of lymphocytes involved because
the assessments were made on hematoxylin and eosin stained
slides. Findings for CD3 cells were conﬂicting. Two studies
identiﬁed no difference in CD3 T cell presence within co-infected
granulomas [31,33], while a third reported a reduction [26]. CD8
T cell presence was also variable. One study demonstrated an
increase in CD8 T cells within granulomas from co-infected per-
sons [33], while two identiﬁed no difference [26,31]. A more
detailed examination of CD8 T cell localization within the gran-
uloma found that, although the number of CD8 T cells were the
same, they were more widely dispersed throughout granulomas
of HIV-1 infected persons, while they were conﬁned to the
lymphocytic mantle surrounding the epithelioid cell layer in HIV-
1 uninfected persons [26]. Two studies reported a statistically
signiﬁcant reduction in CD4 T cells in granulomas of co-infected
persons [26,33] while a third identiﬁed fewer CD4 T cells in
only three of eight persons with HIV-1 co-infection [31]
compared to the HIV-1 uninfected group. The three persons
with fewer CD4 T cells all had <200 pCD4/mm3. The high vari-
ability in T cell staining make it difﬁcult to determine how HIV-1
changes cellular composition.
Macrophage presence within Mtb granulomas were highly
variable. Macrophages are also an essential component of granu-
lomas, forming the epithelioid cell layer. Findings from studies in
this area were also conﬂicting [23,31e33]. Two studies described a
disruption of the epithelioid layer within granulomas in HIV-1
infected persons without deﬁning those disruptions [31,32]. The
presence of Langhan's giant cells, which form when macrophages
fuse and are commonly seen inMtb granulomas, were also variable.
Results from two studies demonstrated no difference in count
[23,33], while another study found fewer Langhan's giant cells in
those co-infected with HIV-1 [31]. Muller et al. [31], determined
that HIV-1 uninfected persons and those with >200 pCD4/mm3
contained more Langhan's giant cells within their granulomas than
HIV-1 uninfected persons. In contrast, granulomas from those with
<200 pCD4/mm3 primarily contained foamy macrophages. Due to
the high variability in macrophage and Langhan giant cells counts,
Figure 4. ManteleHaenszel random effects risk ratio for AFB (A) and CFU (B) presence within excised tissues of HIV-1 co-infected persons.
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presence within granulomas.
3.4. Does HIV-1 change cytokine expression within Mtb
granulomas?
Granulomas contain a delicate balance of pro- and anti-
inﬂammatory cytokine responses [84]. If HIV-1 disrupts this bal-
ance, then Mtb dissemination may occur. Although HIV-1 reduces
IFN-g and TNF production byMtb-speciﬁc T cells in BAL, PF, and PCF
[15e19], it is not known how HIV-1 changes cytokine expression in
granulomas.
Cytokine expression in co-infected granulomas was highly var-
iable and inconclusive. Cytokine expression was also analyzed
within granulomas of co-infected and singly infected persons
[30,31,37] and ﬁndings were again conﬂicting. TNF production
within granulomas was highly variable in co-infected persons.
More granulomatous cells were positive for TNF mRNA in co-
infected persons than HIV-1 uninfected persons [37]. Likewise, a
qualitative trend of more overall TNF production in co-infected
persons with <160 pCD4/mm3 was also observed [31]. De Noro-
nha et al. [30] reported less total TNF produced within granulomas
of HIV-1 co-infected persons with TB lymphadenitis, without
quantiﬁcation. No difference in expression of IL-1a, IL-1b, IFN-a and
IFN-b [31] or the mRNA presence of IFN-g, IL-4 and IL-12p40 [37]
were identiﬁed between the two groups. Foamy macrophages
that replaced epithelioid macrophages in granulomas of four co-
infected persons with <200 pCD4/mm3, were more intensely
stained for IL-1a, IL-1b, IFN-a and IFN-b [31]. The lack of studies and
high variability in staining makes it difﬁcult to quantify how HIV-1
changes cytokine production within Mtb granulomas.
3.5. Does HIV-1 increase the Mtb content of granulomas?
The primary function of a granuloma is to kill Mtb and prevent
its dissemination. HIV-1 increases the risk of extrapulmonary TB
[1]. The increased risk of Mtb dissemination is hypothesized to be
caused by reduced Mtb killing within the granulomas. Todetermine if Mtb granulomas from co-infected persons were more
likely to contain Mtb than HIV-1 uninfected persons, we analyzed
studies that speciﬁcally quantiﬁed either AFBþ or CFUþ samples
out of the total number of excised tissue from both co-infected and
singly infected persons. One study could not be included in this
meta-analysis because their lowest categorical score was deﬁned as
no more than a single bacillary unit was seen in ten microscopic ﬁelds
[28], which could technically represent zero bacilli within ten ﬁelds
(AFB-) or one bacilli (AFBþ).
pCD4 depletion increases the likelihood of Mtb granulomas
containing at least one bacillus, while HIV does not increase bacilli
presence. Of the seven studies that reported the proportion of
AFBþ biopsied tissue within HIV-1 co-infected and uninfected
persons [23e25,31,32,80,82] a high variability of AFBþ rates existed
in both groups with HIV-1 co-infected persons ranging from 1.8
[24] to 75% [32] and HIV-1 uninfected persons from 0 [32] to 62.5%
[31]. HIV-1 did not change AFBþ presence (Figure 4A. RR 1.19 [0.52,
2.71]). Likewise, the seven studies that identiﬁed CFUþ
[23e25,35,36,80,82] did not suggest a difference in bacterial con-
tent (Figure 4B. RR 1.021 [0.89, 1.63]).
As pCD4 decreased the likelihood of granulomas containing at
least one bacillus increased. Two studies found AFBþ presence
inversely correlated with pCD4 counts in HIV-1 infected persons
[23,28]. Biopsies from co-infected persons with <100 pCD4/mm3
were more likely to be AFBþ (43%, 6/14) than co-infected persons
with >100 pCD4/mm3 (8%, 3/36) [23]. The depletion of pCD4 T cells
led to increases in Mtb presence within granulomas.
HIV-1 increased the amount of Mtb in granulomas. Three
studies quantiﬁed AFB load in excised tissues in each group
[23,28,32]. One study quantiﬁed AFB load between a low1 AFB to
a high of >10 AFB per 100 ROI [28], another identiﬁed the number
of tissue samples with either numerous vs. scanty AFB [23], and the
ﬁnal study categorically assigned absent to abundant AFB [32]
without a description. The forest plot and subsequent calculated
risk ratio for HIV-1 infected persons identiﬁed an increased AFB
load within AFBþ tissue (Figure 5. RR 4.30 [1.07, 17.18]). Di Perri
et al. [28], identiﬁed an inverse correlation between pCD4 count
and AFB load within excised tissue from co-infected persons.
Figure 5. ManteleHaenszel random effects risk ratio for abundant AFB load in HIV-1 co infected persons.
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BACTEC culture in excised pleural tissue [35]. HIV-1 infection ap-
pears to increase Mtb abundance within individual granulomas.
3.6. Does HIV-1 preferentially infect TB diseased tissue?
TB granulomas have been hypothesized to be preferential sites
of HIV-1 replication (Table 1) [4,5,12]. If HIV-1 preferentially lo-
calizes within granulomas then the virus would have a better
chance of killing Mtb-speciﬁc T cells and Mtb-infected macro-
phages because of their high prevalence within granulomas. This
speciﬁc killing could lead to increased Mtb growth.
HIV-1 infects Mtb granulomas. Van der Ende et al. [38] quali-
tatively examined HIV-1 RNA presence within T cells and macro-
phages in lymph nodes from ﬁve persons with >150 pCD4/mm3 to
two persons with <50 pCD4/mm3. In the former group, there were
well-organized granulomas and the number of HIV-1 RNAþ cells
was 10-fold higher in or near granulomas compared to other non-
granulomatous areas. In those persons with pCD4 counts <50
pCD4/mm3, HIV-1 RNAþ cells were distributed more evenly
throughout the lymph node, independent of the inﬂammatory
inﬁltrate. CD4 T cells were the dominant source of HIV-1 RNA
within most of the lymph nodes. These ﬁndings were based on a
small sample size and were only presented as an overall impression
rather than by individual ﬁndings. HIV-1 viral RNA was also iden-
tiﬁed with PCR in homogenized spinal tissue that contained gran-
ulomas [33], but it was not possible to determine if virus originated
in the granuloma or surrounding tissue. HIV-1 does localize within
Mtb granulomas, but more studies need to be performed to conﬁrm
what cells are preferentially infected.
4. Discussion
It has been hypothesized that HIV-1 increases TB susceptibility
by reducing the formation and function of Mtb granulomas. Studies
that have examined Mtb granulomas directly in HIV-1 co-infected
persons have not been collated until now. We performed thisTable 3
Guidelines for future granuloma-based studies.
Category Recommendations for future granuloma-based studies
Granuloma
descriptions
 Include detailed descriptions of all granuloma scores fo
authors should provide example images upon request
 Detail how scores were tabulated. Were all granulomas
 Present the range of granuloma scores within each ind
 Explain how each granuloma or region of interest was
 Only compare granulomas that reside in the same tiss
Study groups  HIV-1 and TB diagnoses should be included for all pat
 HIV-1 studies should include pCD4 counts
 Drug treatment should be stated
Study design  Were the observer's blinded?
 Describe how each parameter was speciﬁcally quantiﬁ
 Were their enough persons to justify conclusions?
 Autopsy studies should state how long the subject was
it required to ﬁx the tissue.systematic review and meta-analysis to determine which hypoth-
eses could be conﬁrmed by the human literature and which ones
needmore research. Despite the strong epidemiological association
between TB and HIV-1s [12], research into how HIV-1 manipulates
the Mtb granuloma was conﬂicting and quite limited.
One outcome with consistent ﬁndings and a signiﬁcant differ-
ence between the HIV-1 infected and uninfected groups was
bacillary load. In the three studies that examined this outcome,
HIV-1 co-infected persons consistently demonstrated greater
bacillary load [23,28,32]. This was the only ﬁnding that provided
some potential explanation for the increased susceptibility to more
severe TB disease in HIV-1 infected persons. However, when
studies were stratiﬁed by pCD4 counts [23,28,31,35,38], results
were more consistent. Lower pCD4 counts were associated with
increased bacillary presence [23,28], inﬂammatory cytokine pro-
duction by foamy macrophages [31], and poorer granuloma for-
mation [28,31,38]. These data suggest that as HIV-1 disease
progresses, the ability to maintain normal granuloma function
becomes impaired. These ﬁndings also illuminate the importance
of stratifying pCD4 counts when analyzing outcomes from HIV-1
infected persons to achieve more accurate and consistent ﬁnd-
ings. Consideration of other clinical characteristics including
duration of TB disease or symptoms, gender, age, HIV-1 and TB
treatment status, and previous TB disease may also help to improve
the consistency of ﬁndings.
In all other outcomes, there was high variation between studies,
both in terms of methods used to assess outcomes, and also their
results. Heterogeneity scores for all measured outcomes were
moderate to high, and the summative risk ratios had very wide
conﬁdence intervals for the outcomes of granuloma presence, for-
mation quality and AFB presence when comparing TB diseased
tissue from HIV-1 infected and HIV-1 uninfected persons. In terms
of studies' outcomes such as cellular composition of granulomas
and cytokine expression, ﬁndings were also conﬂicting and no
trend could be extracted. There was also a surprising lack of data
that focused on the effect Mtb bacilli had upon the distribution of
HIV-1 transcripts. Studies that only described ﬁndings from TBr individual types of granulomas with reference images (if space is limited then the
).
counted and averaged? Do certain granulomas skew results because of their size?
ividual as well as each group.
chosen to be scored (random selection?)
ue type among persons to reduce variability.
ients
ed instead of using vague subjective terms such as “abundant” or “scanty”.
dead prior to autopsy and studies that focus on excised tissue should state the time
Table 4
Questions that still need to be answered within the HIV-1/Mtb co-infection literature.
Category Questions
Compositional
changes
 Does HIV-1 signiﬁcantly change granuloma formation?
 Do HIV-1 and AFB presence correlate in infected tissue?
 Does HIV-1 signiﬁcantly reduce CD4 T cell counts within granulomas?
Functional
changes
 Does HIV-1 signiﬁcantly reduce Mtb-speciﬁc T cell functionality (chemokine and cytokine production or cytolytic activity) within granulomas
more than within the periphery?
 Does pCD4 T cell depletion correlate to increased changes within granulomas?
 How do functional T cell responses correlate among PBMC, BALF, PF, and within granulomas and does this correlate to disease status?
HIV-1 and ART
focused
research
 Does HIV-1 preferentially replicate within granulomas? Which cells are preferentially infected within granulomas and the surrounding tissue?
 Do HIV-1 and Mtb co-localize within the same cells or within close proximity inside of granulomas?
 Does anti-viral penetration of granulomas correlate to improved granuloma function, organization, reduced viral titers, or patient outcome?
Identifying
biomarkers
 Does anti-viral penetration into granulomas correlate to pharmacokinetics observed within the plasma?
 What blood biomarkers correlate to signiﬁcant changes in granuloma function?
C.R. Diedrich et al. / Tuberculosis 98 (2016) 62e7674diseased tissue from HIV-1 infected persons that did not stratify
pCD4 counts or make comparisons to HIV-1 uninfected persons
were excluded from our review. However, data from the studies we
excluded [39e46] revealed similar variability in ﬁndings, particu-
larly in regards to granuloma formation and AFB presence
(Supplemental Table 2). Heterogeneity and the high variability
among techniques used may have reduced consistency in ﬁndings
among the studies examined in this review. Some of the variability
among these studies may have been reduced if they had been
better powered.
High variability in methods used for each study may have
limited our ﬁndings. As previously mentioned, where semi-
quantiﬁed scoring systems were used to quantify outcomes such
as granuloma formation or AFB load, methods either varied or were
not described. The methods scoring outcomes varied considerably:
poorly- or well-formed granulomas [23,27,31],well-formed with giant
cells [35], scanty or numerous AFB [23], rare or abundant AFB [32],
þþþ orþ AFB [30] and other semi-quantiﬁed scores [28,30e32,81].
These terms were often applied without speciﬁc deﬁnition and as
such were open to subjective interpretation and observer bias [85].
A signiﬁcant variation likely existed in how individual tissues were
scored among the studies and it was difﬁcult to identify the effect
this had on our overall results.
A second concern was that for semi-quantiﬁed variables, in
particular quality of granuloma formation, results were repre-
sented by a single score. This score may have failed to represent the
range of granulomas or unorganized inﬂammation that was likely
located within a single tissue section. Granulomas are highly vari-
able in terms of size, histological type [6], formation quality [31],
cytokine expression [84], and bacterial load [86]. It was not clear in
these studies whether this variability was assessed or how it was
handled when choosing how to score the tissues. Conceivably, a
number of strategies may have been adopted if such variations
were present, including scoring by the largest granulomas, the
most numerous, a random selectionwithin the tissue, or an average
of all granulomas present. Without knowing which methods were
used to provide an overall score for tissues, the implication for
potential bias was difﬁcult to ascertain. The high variability in
ﬁndings may have been reduced if all granulomas identiﬁed within
each tissue was represented, along with exactly how each granu-
loma was selected and scored. Only one study speciﬁcally stated
that the assessing pathologists were blinded [30], which could have
reduced the risk of observer bias [85].
While the studies we reviewed assessed the effect of HIV-1 on
Mtb granulomas, we have demonstrated there was little that could
be conclusively stated about how HIV-1 changes the site of TB
disease. The primary issue we identiﬁed was that ﬁndings from
different studies could not always be compared, despite having
examined the same outcomes. To increase comparability of future
studies we have developed a basic guideline for research on thepathology of HIV-1/Mtb co-infection (Table 3) because important
unanswered questions need further exploration (Table 4).
The objective of our guidelines are to ensure that future studies
provide enough detail through a reduced-biased methodology that
will allow other researchers to compare results. We also encour-
aged open access to examined images of Mtb-infected tissues
within these studies. This would facilitate researchers' ability to
evaluate their peers' analyses of these tissues and minimize
redundant research effort. Implementing both these guidelines and
open access to pathology images in future work would help build
consensus on their criteria needed to properly assess granulomas,
even if the number of available samples are small in individual
studies. Increasing the cohesiveness of data will heavily contribute
to the overall understanding of how HIV-1 alters immunity at the
site of TB disease. We hope this will provide a greater under-
standing of the dynamics of this co-infection at the local level,
which in turn may lead to novel interventions and therapies tar-
geting the microenvironment of granulomas.
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